Limits...
Reliable measurements of brain atrophy in individual patients with multiple sclerosis

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: As neurodegeneration is recognized as a major contributor to disability in multiple sclerosis (MS), brain atrophy quantification could have a high added value in clinical practice to assess treatment efficacy and disease progression, provided that it has a sufficiently low measurement error to draw meaningful conclusions for an individual patient.

Metrixmetrix: In this paper, we present an automated longitudinal method based on Jacobian integration for measuring whole‐brain and gray matter atrophy based on anatomical magnetic resonance images (MRI), named MS. MS is specifically designed to measure atrophy in patients with MS, by including iterative lesion segmentation and lesion filling based on FLAIR and T1‐weighted MRI scans.

Metrixmetrixmetrixmetrix: MS is compared with SIENA with respect to test–retest error and consistency, resulting in an average test–retest error on an MS data set of 0.13% (MS) and 0.17% (SIENA) and a consistency error of 0.07% (MS) and 0.05% (SIENA). On a healthy subject data set including physiological variability the test–retest is 0.19% (MS) and 0.31% (SIENA).

Metrix: Therefore, we can conclude that MS could be of added value in clinical practice for the follow‐up of treatment and disease progression in MS patients.

No MeSH data available.


Comparison of whole‐brain percentual volume change obtained by MSmetrix‐long and SIENA in 20 MS patients, five time points each
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036437&req=5

brb3518-fig-0006: Comparison of whole‐brain percentual volume change obtained by MSmetrix‐long and SIENA in 20 MS patients, five time points each

Mentions: On a longitudinal data set of patients with MS (data set 3), the correlation between whole‐brain atrophy measurements obtained with MSmetrix‐long and SIENA is relatively high, with a Pearson correlation coefficient equal to 0.91 and an intraclass correlation coefficient of 0.90. Figure 6 presents the scatter plot of the percentage whole‐brain volume changes of MSmetrix‐long with respect to SIENA's for 6‐months, 1‐year, and 2‐year atrophy for all 20 patients.


Reliable measurements of brain atrophy in individual patients with multiple sclerosis
Comparison of whole‐brain percentual volume change obtained by MSmetrix‐long and SIENA in 20 MS patients, five time points each
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036437&req=5

brb3518-fig-0006: Comparison of whole‐brain percentual volume change obtained by MSmetrix‐long and SIENA in 20 MS patients, five time points each
Mentions: On a longitudinal data set of patients with MS (data set 3), the correlation between whole‐brain atrophy measurements obtained with MSmetrix‐long and SIENA is relatively high, with a Pearson correlation coefficient equal to 0.91 and an intraclass correlation coefficient of 0.90. Figure 6 presents the scatter plot of the percentage whole‐brain volume changes of MSmetrix‐long with respect to SIENA's for 6‐months, 1‐year, and 2‐year atrophy for all 20 patients.

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: As neurodegeneration is recognized as a major contributor to disability in multiple sclerosis (MS), brain atrophy quantification could have a high added value in clinical practice to assess treatment efficacy and disease progression, provided that it has a sufficiently low measurement error to draw meaningful conclusions for an individual patient.

Metrixmetrix: In this paper, we present an automated longitudinal method based on Jacobian integration for measuring whole‐brain and gray matter atrophy based on anatomical magnetic resonance images (MRI), named MS. MS is specifically designed to measure atrophy in patients with MS, by including iterative lesion segmentation and lesion filling based on FLAIR and T1‐weighted MRI scans.

Metrixmetrixmetrixmetrix: MS is compared with SIENA with respect to test–retest error and consistency, resulting in an average test–retest error on an MS data set of 0.13% (MS) and 0.17% (SIENA) and a consistency error of 0.07% (MS) and 0.05% (SIENA). On a healthy subject data set including physiological variability the test–retest is 0.19% (MS) and 0.31% (SIENA).

Metrix: Therefore, we can conclude that MS could be of added value in clinical practice for the follow‐up of treatment and disease progression in MS patients.

No MeSH data available.